Weikang Bio-Technology Group Co. (WKBT), today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
"We are working extremely diligent to enhance our market penetration as we continue to build a high-quality therapeutics company. We have launched several new therapeutics this year and have plans to launch several more new therapeutics in 2011. In addition, we have expanded our sales coverage area by adding three new distributors," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Therefore, we believe that we have created a solid foundation to continue expanding sales, increase revenue and net income and strengthen shareholder value."
I like it when management gives a guidance, that means that they are confident with their business.
POSITION: LONG
Monday, November 29, 2010
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment